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The UK Coronavirus Cancer Monitoring Project (UKCCMP) aims to collect, analyse, and 
disseminate in real time data from the UK cancer centres about SARS-CoV-2 infection rates in 
patients with cancer, and their outcomes in terms of COVID-19. This approach will enable 
oncologists to gain crucial insights to inform decision-making. 
 
In December, 2019, several cases of acute respiratory syndrome in Hubei province, China were 
identified; these were the first described cases of coronavirus disease 2019 (COVID-19). The 
causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new strain of 
betacoronavirus previously not identified in humans and thought to be of zoonotic origin.1 The 
presentation of COVID-19 varies from no or minor symptoms akin to the common cold, to severe 
acute respiratory distress syndrome, resulting in severely impaired respiratory function.1 SARS-
CoV-2 is highly contagious through direct transfer of respiratory droplets during coughing and 
sneezing or indirect fomite spread via contaminated surfaces. This simple transmission, coupled 
with international travel, has enabled rapid spread of the virus with more than 870 000 cases and 
43 000 deaths reported worldwide as of April 1, 2020.2 
 
Approximately 2·5 million individuals live with, or have a history of, cancer in the UK, with 1000 
new diagnoses each day.3 Of these patients, a substantial proportion require, are undergoing, or 
are recovering from surgery and complex treatments. Patients with cancer potentially have 
increased susceptibility to SARS-CoV-2 infection and have more serious sequelae, resulting from 
impaired immune function due to cancer itself, cancer treatment, or both.4,5 
 
In China, Wenhua Liang and colleagues5 reported their identification of 18 patients with cancer in 
a cohort of 1590 patients with COVID-19, indicating an increased incidence of COVID-19 in 
patients with cancer compared with the general Chinese population (1·13% vs 0·29%). This 
observation was also suggested by Yu and colleagues6 who investigated SARS-CoV-2 infection in 
patients with cancer at a tertiary care hospital in Wuhan. The incidence of COVID-19 in patients 
with cancer (12 [0·79%] of 1524 patients) was higher than in the general Wuhan population 
(0·37%). 
 
Patients with specific types of cancer might be at an increased risk of COVID-19, with both these 
reports highlighting the high proportion of patients with lung cancer with confirmed diagnoses of 
COVID-19 (five of 18 patients in Liang et al,5 and seven of 12 in Yu et al6). Specific cancer 
treatments might also differentially contribute to risk of COVID-19. Severe COVID-19 infection is 
associated with cytokine storm and increased concentrations of C-reactive protein and IL-6 
pneumonitis, severe adverse events that are also associated with immune checkpoint inhibitor 
therapy.7 Consequently, COVID-19 might cause more harm in patients receiving immunotherapy. 
Furthermore, cytotoxic treatments used for haematological malignancies diminish lymphocyte 
populations, potentially rendering patients more susceptible to infection. Conversely, many cancer 
treatments for solid tumours have little effect on lymphocyte populations or inflammatory 
responses. Therefore, SARS-CoV-2 infection is highly unlikely to affect all patients with cancer 
equally. 
 
The European Society of Medical Oncology has published guidelines on how to mitigate the effect 
of COVID-19 on patients with cancer, by prioritisation of cancer treatment in patients expected to 
derive a substantial absolute survival benefit, reducing hospital visits, and converting from 
intravenous to oral regimen.8 However, these guidelines take a broad approach for a very 
heterogenous population. Policies, including self- isolation and social distancing, are widely 
acknowledged to be required to suppress viral spread, both in the general and at-risk populations, 
thereby reducing pressure on already stretched health-care resources.9 However, substantial 
reallocation of resources away from cancer care services could potentially have unintended 
cancer-related implications, including increased morbidity and mortality. Therefore, real-time 
collection, analysis, and dissemination of data from our cancer centres about SARS-CoV-2 infection 
rates in patients with cancer, and their disease outcomes, is needed. 
 
The UKCCMP, launched on March 18, 2020, and aiming to involve over 90% of UK cancer centres, 
will achieve this goal. A Local Emergency Response Reporting Group has been created at each UK 
cancer centre to ensure continued updating of the UKCCMP. The project will collect data on 
patients with cancer who are positive for SARS-CoV-2 infection, including tumour type and stage, 
patient age, present cancer treatment, and clinical outcomes, with the aim to enable oncologists 
to gain crucial insights to inform decision making. Data collection, analysis, and dissemination is 
coordinated by the Centre for Computational Biology at the University of Birmingham, 
Birmingham, UK, through a dedicated workflow hosted by the Compute and Storage for Life 
Science infrastructure as part of the Birmingham Environment for Academic Research local 
Cloud.10 
 
UKCCMP delivers meaningful real-time data to all UK cancer centres and clinicians to allow more 
personalised approaches to individual patient care and inform clinical decision making. This 
initiative will improve cancer care in the UK and beyond at this time of unprecedented global 
turmoil and call on health-care resources. 
 
Members of the UK Coronavirus Cancer Monitoring Project team are listed in the appendix (p 1). 
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